- Home
- EMX vs VNDA Comparison
EMX vs VNDA Comparison
Compare EMX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- VNDA
- Stock Information
- Founded
- EMX N/A
- VNDA 2002
- Country
- EMX Canada
- VNDA United States
- Employees
- EMX N/A
- VNDA N/A
- Industry
- EMX
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- VNDA Health Care
- Exchange
- EMX Nasdaq
- VNDA Nasdaq
- Market Cap
- EMX 261.3M
- VNDA 288.2M
- IPO Year
- EMX N/A
- VNDA 2006
- Fundamental
- Price
- EMX $2.80
- VNDA $4.78
- Analyst Decision
- EMX Strong Buy
- VNDA Strong Buy
- Analyst Count
- EMX 1
- VNDA 3
- Target Price
- EMX $5.00
- VNDA $15.33
- AVG Volume (30 Days)
- EMX 393.8K
- VNDA 421.0K
- Earning Date
- EMX 08-11-2025
- VNDA 07-30-2025
- Dividend Yield
- EMX N/A
- VNDA N/A
- EPS Growth
- EMX N/A
- VNDA N/A
- EPS
- EMX 0.00
- VNDA N/A
- Revenue
- EMX $29,630,000.00
- VNDA $201,351,000.00
- Revenue This Year
- EMX N/A
- VNDA $16.86
- Revenue Next Year
- EMX $12.71
- VNDA $39.78
- P/E Ratio
- EMX $1,514.46
- VNDA N/A
- Revenue Growth
- EMX N/A
- VNDA 13.37
- 52 Week Low
- EMX $1.59
- VNDA $3.81
- 52 Week High
- EMX $2.90
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- EMX 69.23
- VNDA 53.88
- Support Level
- EMX $2.66
- VNDA $4.85
- Resistance Level
- EMX $2.90
- VNDA $5.12
- Average True Range (ATR)
- EMX 0.09
- VNDA 0.18
- MACD
- EMX 0.02
- VNDA 0.01
- Stochastic Oscillator
- EMX 79.41
- VNDA 54.05
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.